Glaxosmithkline Share News (GSK)

CORRECT: LONDON MARKET OPEN: Oil stocks lift FTSE amid China concerns

(Correcting Fresnillo is gold and silver miner, and Comision Federal de Electricidad is Mexican state-owned power company.)

LONDON MARKET OPEN: Oil stocks lift FTSE 100; China concerns persist

(Alliance News) - London's FTSE 100 index was outperforming on Tuesday morning as a rising Brent price lifted its heavyweight oil stocks, while other equities were shaken by further Covid measures in China.

TOP NEWS: GSK suffers setback as FDA demands withdrawal of cancer drug

(Alliance News) - GSK PLC on Tuesday said it has started the process to withdraw US marketing authorisation for its cancer drug, Blenrep, on the request of the US Food & Drug Administration.

GSK starts moves to pull FDA approval for blood cancer drug

(Sharecast News) - British pharmaceutical giant GSK on Tuesday said it has started proceedings to pull US approval for its blood cancer drug Blenrep after it failed to meet the requirements of a late-stage trial.

LONDON BRIEFING: FTSE 100 called higher as oil prices firm overnight

(Alliance News) - Stocks in London were called slightly higher on Tuesday, as a rising Brent oil price supported the FTSE 100 index, despite unease over Covid-related developments in China.

FTSE 100 eases as China COVID surge knocks energy, mining stocks

Oil, mining stocks lead losses on FTSE 100

*

Britain's Mitie offers workers winter support package

Worker support includes bonuses, discounts, loans

*

Britain's NICE recommends against NHS use of 5 COVID treatments as not cost-effective

LONDON, Nov 16 (Reuters) - Britain’s agency that determines if medicines should be used in the National Health Service (NHS), has recommended stopping the use of five COVID-19 treatments, including Merck & Co's's antiviral pill for high-risk patients, citing cost-effectiveness concerns.

Big pharma not doing enough to improve drug access - analysis

LONDON, Nov 15 (Reuters) - Since the pandemic emerged, more top drugmakers have made progress in improving access to medicines in the developing world, but those gains are largely limited to middle-income countries leaving the poorest behind, an analysis has found.

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

GSK's oncology business suffers fresh blow with Zejula setback

News follows setback to GSK's blood cancer drug Blenrep

*

GSK to restrict US use of cancer drug Zejula to some populations

(Alliance News) - GSK PLC on Friday said it will restrict the use of its niraparib, sold under the brand name Zejula, to patients in the US.

Second-line use of GSK cancer drug restricted

(Sharecast News) - The second-line application of a GSK cancer treatment will be limited following a request by the US regulators, the drugs giant said on Friday.

Much of biopharma industry yet to set climate impact targets - report

LONDON, Nov 9 (Reuters) - Much of the global pharmaceutical and biotech industry has yet to set any targets for reducing carbon emissions in line with the Paris Agreement, a new analysis has found, despite the biggest companies in the sector leading the way.

LONDON MARKET CLOSE: Cooling US inflation triggers risk-on rally

(Alliance News) - Equities in Europe were celebrating a cooler-than-expected US CPI print on Thursday, which gave rise to hopes that peak inflation in the US has passed.